Tue 09/26/2023 12:14 PM
Relevant Document:
H1’23 Financials
Distressed debt investors are monitoring Swiss drug producer Idorsia’s bonds, which are falling in price amid a substantial cash burn in H1’23 and dwindling liquidity, sources told Reorg.
Following a slower-than-planned rollout of its Quviviq insomnia drug, Idorsia has launched a cost and portfolio review and is actively looking at raising new equity or a third convertible bond to see the group through 2024, management told investors in late...
This article is an example of the content you may receive if you subscribe to a product of Reorg Research, Inc. or one of its affiliates (collectively, “Reorg”). The information contained herein should not be construed as legal, investment, accounting or other professional services advice on any subject. Reorg, its affiliates, officers, directors, partners and employees expressly disclaim all liability in respect to actions taken or not taken based on any or all the contents of this publication. Copyright © 2024 Reorg Research, Inc. All rights reserved.